Non-invasive co-delivery of Axitinib and telmisartan via LDH-based nanocarriers for synergistic VEGF/Ang-2 inhibition in ocular neovascular diseases
- 23 December 2025
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 390, 114574
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Treatment avenues for age-related macular degeneration: Breakthroughs and bottlenecksAgeing Research Reviews, 2024
- Severe Intraocular Inflammation Following Intravitreal FaricimabJAMA Ophthalmology, 2024
- Emerging Co‐Assembled and Sustained Released Natural Medicinal Nanoparticles for Multitarget Therapy of Choroidal NeovascularizationAdvanced Materials, 2024
- Targeted long-term noninvasive treatment of choroidal neovascularization by biodegradable nanoparticlesActa Biomaterialia, 2023
- Faricimab: First ApprovalDrugs, 2022
- Rational design of mixed nanomicelle eye drops with structural integrity investigationActa Biomaterialia, 2022
- Hyaluronic acid in ocular drug deliveryCarbohydrate Polymers, 2021
- Multifunctional nanocomposite eye drops of cyclodextrin complex@layered double hydroxides for relay drug delivery to the posterior segment of the eyeCarbohydrate Polymers, 2021
- Multifunctional carboxymethyl chitosan derivatives-layered double hydroxide hybrid nanocomposites for efficient drug delivery to the posterior segment of the eyeActa Biomaterialia, 2020
- Functional chitosan oligosaccharide nanomicelles for topical ocular drug delivery of dexamethasoneCarbohydrate Polymers, 2020